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ValidationBackground: A neuroinﬂammatory response is suggested to play an important role in delirium, a common com-
plication in older hospitalized patients. We examined whether hip fracture patients who develop postoperative
delirium have a different proteome in cerebrospinal ﬂuid (CSF) prior to surgery.
Methods: Patients (≥75 years) were admitted for hip fracture surgery. CSF was collected during spinal anaesthe-
sia; proteins were separated using gel electrophoresis and identiﬁed with mass spectrometry. We compared the
proteome of patients with and without postoperative delirium. Findings were validated in an independent,
comparable cohort using immuno-assays.
Results: In the derivation cohort 53 patients were included, 35.8% developed postoperative delirium. We identi-
ﬁed differences in levels of eight CSF proteins between patients with and without subsequent delirium: comple-
ment factor C3, contactin-1, ﬁbulin-1 and I-beta-1,3-N-acetylglucosaminyltransferasewere signiﬁcantly lower in
patients with postoperative delirium, while neural cell adhesion molecule-2, ﬁbrinogen, zinc-α-2-glycoprotein
and haptoglobin levels were signiﬁcantly higher. In the validation cohort 21.2% of 52 patients developed
postoperative delirium. Immuno-assays conﬁrmed contactin-1 results although not statistically signiﬁcant.
Complement factor C3 was signiﬁcantly higher in patients with postoperative delirium.
Conclusion: Our results show the complexity of pathophysiological mechanisms involved in delirium and
emphasizes the need of independent validation of ﬁndings.
General signiﬁcance: This study highlights the challenges and inconsistentﬁndings in studies of delirium, a serious
complication in older patients. We analysed proteins in CSF, the most proximal ﬂuid to the brain. All patients
were free from delirium at the time of sampling.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).gel electrophoresis; b3GNT3, N-
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Delirium is the most common complication in hospitalized older
patients and is known to be associated with both short- as well as
long-term detrimental outcomes [1]. The exact pathophysiological
mechanisms in delirium and its associated poor outcomes are still un-
known, but a neuroinﬂammatory response has been suggested to play
a role [2]. Neuroinﬂammation may arise in response to peripheral in-
sults, such as infection, surgery and fracture [3]. The communicationthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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microglia, the innate immune cells of the central nervous system. In
response to activation, microglia release a range of inﬂammatory
mediators, inﬂuencing neuronal function and possibly inducing
delirium in susceptible individuals [4]. Aging and neurodegenerative
disease are well known predisposing risk factors for delirium [3] and
are both accompanied by a pro-inﬂammatory state [4]. Older people
are especially vulnerable, since impaired cholinergic inhibition can elicit
increased microglia activation and inﬂammation, which may result in
neuronal damage [4].
Previous research revealed that hip fracture patients who develop
postoperative delirium show lower preoperative cerebrospinal ﬂuid
(CSF) concentrations of anti-inﬂammatory cytokines compared to pa-
tients who do not develop postoperative delirium [5]. This ﬁnding is
consistent with a role for a dysfunctional neuroinﬂammatory response
in delirium. However, inﬂammation is a highly complex and dynamic
process in which many different effectors interact. The state of inﬂam-
mation is not likely to be dependent on the net effect of individual
cytokines only, but on the balance between numerous pro- and anti-
inﬂammatory mediators in the central nervous system [6].
A recent study assessed the CSF proteome in patients with delirium,
and found 16 dysregulated proteins, including acute phase proteins like
complement C3, ﬁbrinogen and haptoglobin, providing supplementary
evidence that inﬂammation is involved in delirium [7].
We hypothesized that elderly hip fracture patients who develop
postoperative delirium, have speciﬁc CSF protein proﬁles prior to
operation, as compared to patients who do not develop postoperative
delirium. Differences in the CSF proteome can be assessed using two-
dimensional difference gel electrophoresis (2D-DIGE), a technique fre-
quently used in research on potential CSF biomarkers in neurological
diseases such as Parkinson's and Alzheimer's disease, multiple sclerosis,
and amyotrophic lateral sclerosis [8–11]. We used this technique to
compare the pre-operative CSF proteome of patientswith postoperative
deliriumwith that of patients without delirium after surgery. Proteomic
ﬁndingswere validated in a separate, comparable cohortwith immuno-
assays.
2. Methods
The study was approved by the medical ethical committees of
both hospitals where patients were included, and was conducted in
accordance with the guidelines of Good Clinical Practice. All patients
gave written informed consent.
2.1. Patients
CSF for proteomic analysis (derivation cohort) was collected in a
teaching hospital in Alkmaar, The Netherlands between March 2008
and March 2009. Patients participated in a double blind randomized
study comparing effectiveness of taurine versus placebo in reducing
morbidity and 1-year mortality in elderly hip fracture patients [5].
Patient recruitment and study procedures for the proteomics study
have been described in detail elsewhere [5]. In brief: all patients of
75 years or older who were admitted for surgical repair of a hip frac-
ture were assessed for eligibility. Patients were excluded if they had
no acute trauma or a pathological fracture, received total hip pros-
thesis, had contraindications regarding the administration of taurine
(that is, renal failure deﬁned as a creatinine clearance b30 ml/min),
or did not provide consent. The Informant Questionnaire on Cogni-
tive Decline Short Form (IQCODE-sf) was completed by the primary
caregiver. Cognitive impairment was deﬁned as a score of 3.4 or
higher on this questionnaire or a record of dementia in the medical
history.
Themain outcomewas postoperative delirium, deﬁned according to
the Confusion Assessment Method [12]. The presence of delirium was
assessed daily from admission until the ﬁfth postoperative day. Toassess risk factors for delirium instead of markers of delirium, all pa-
tients with preoperative delirium were subsequently excluded from
analysis. Because all participants were at high risk of delirium, they all
received routine care with prophylactic treatment of 0.5 mg haloperi-
dol, three times daily from admission until postoperative day three,
unless contraindications were present [13].
To check whether preoperative protein differences between groups
represent reproducible, clinically relevant changes in patients with
postoperative delirium,we performed a validation study in an indepen-
dent cohort. CSF for validation, using immuno-assays, was collected in a
teaching hospital in Amsterdam, The Netherlands betweenMarch 2012
and April 2014. Patients were participants in a prospective descriptive
cohort study assessing incidence, prevalence and pathophysiology of
delirium. All patients of 65 years or older who were admitted for
surgical repair of a hip fracture were checked for eligibility. Patients
were excluded if they were discharged or died within 48 h after
inclusion, did not receive spinal anesthesia or if no communication
was possible (e.g. aphasia, language barrier, deafness). In the validation
cohort, the IQCODE-sf was also completed by the primary caregiver. To
make sure patients included in the validation cohort would be
comparable to those in the derivation cohort,we subsequently excluded
patients who were younger than 75 years, had no acute trauma or a
pathological fracture, received total hip prosthesis, or had pre-
operative delirium. The main outcome was postoperative delirium,
assessed daily by trained nursing staff using the delirium observation
screening scale [14]. In case of a score of 3 or higher, a psychiatrist
was consulted to assess delirium as deﬁned in the fourth edition of
the Diagnostic and Statistical manual of Mental disorders [15]. If
necessary, patients received treatment with haloperidol according to
local clinical practice.
2.2. CSF samples
CSF samples for the proteomics and validation studies were collect-
ed according to the same procedures: during cannulation for the
introduction of spinal anaesthesia, always prior to administration of
any anaesthetic. Of each patient CSF was collected in polypropylene
tubes which were transported to the laboratory within 15 min after
withdrawal. Upon arrival at the laboratory the CSF samples were
centrifuged, aliquoted into polypropylene tubes, and stored at−80 °C.
2.3. 2D-DIGE
To analyse the CSF proteome, we adapted a protocol previously de-
scribed in more detail [16]. In brief: of each patient, 2 ml of CSF sample
was spundown and the supernatantwas precipitated in 80% action. The
protein pallet was resuspended and the protein concentration was esti-
mated by the Bradfordmethod using bovine serum albumin as standard
(Bio-Rad, Hercules, CA, USA). Protein extracts were labelled using
the ﬂuorescent cyanine dyes developed for 2D-DIGE technology
(GE Healthcare, Little Chalfont, Buckinghamshire, UK). Protein extracts
(40 μg) were labelled with 333 pmol of ﬂuorescent dye (Cy2, Cy3 or
Cy5). Samples were randomly labelled with Cy3 or Cy5 to avoid dye re-
lated bias. An internal control sample, to avoid inter-gel variations, was
created by pooling 20 μg of each protein sample and was labelled with
Cy2. Three protein samples (Cy3, Cy5 and Cy2) were pooled and pas-
sively loaded onto 24 cm pH 3–10 NL strips (GE Healthcare), followed
by isoelectric focussing using a manifold-equipped IPGphor IEF unit
(GE Healthcare). Second dimensional SDS-PAGE was performed on
hand-cast 12% SDS-PAGE gels using low ﬂuorescence glass plates. Elec-
trophoresis was carried out at 1 W per gel until completion using an
Ettan DALT-12 unit (GE Healthcare). Gels were scannedwith a Typhoon
9410 imager (GE Healthcare). Spot detection was performed with
DeCyder 7.0 software (GE Healthcare): the Cy2, Cy3 and Cy5 images
for each gel were merged, spot boundaries are automatically detected
and spot volumes are calculated. This analysis was used to calculate
Table 1
Patient characteristics.
Derivation
N = 53
Validation
N = 52
p-Value
Age (years). median, (IQR) 83.1 (79.6–87.0) 87.5 (81.0–90.5) 0.011
Female. n (%) 36 (67.9) 37 (71.2) 0.833
Living independently. n (%) 34 (64.2) 35 (67.3) 0.839
Number of co-morbid diseases.
Median (IQR)
2 (1–2) 2 (1–3) 0.420
Cognitive impairment. n (%) 14 (26.4) 13 (25.0) 0.868
Time between admission and
surgery (days). Median (IQR)
1 (1–2) 1 (0–1) b0.001
Postoperative delirium. n (%) 19 (35.8) 11 (21.2) 0.130
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in the resulting ‘spot-map’ were matched after extensive landmarking
and automatic matching. Dividing each Cy3 or Cy5 spot volume by the
corresponding Cy2 (internal control) spot volume within each gel
corrected for inter-gel variations.
For spot-picking, 600 μg of unlabelled protein extract was separated
and stained with Flamingo ﬂuorescent stain (Bio-Rad) following the
manufacturer's protocol. We compared the Flamingo stained prepara-
tive gel with the DIGE master image, designated the differentially
expressed spots manually in the preparative gel, and picked the protein
spots with an automated spot picker (Bio-Rad).
2.4. Liquid chromatography–mass spectrometry (LC–MS/MS) analysis
After picking, the gel spots were reduced and alkylated, and the
proteins were digested. After incubation the peptides were extracted
and dried in vacuo. Of each sample, ﬁve percent was injected on the
LC–MS system, [17] a LTQ Finnigan (Thermo Fisher Scientiﬁc, Bremen,
Germany) connected to an Agilent 1200 HPLC system (Agilent Technol-
ogies, Amstelveen, The Netherlands) adapted for nanoﬂow LC separa-
tion [18]. All columns were packed in-house [18,19]. Nanospray was
achieved using a distally coated fused silica emitter made in-house bi-
ased to 1.7 kV. The mass spectrometer was operated in the positive
ion mode and parent ions were selected for fragmentation in data de-
pendent mode to automatically switch between MS and MS/MS. The
most intense ions above the threshold of 500 were fragmented in the
ion trap using collision-induced dissociation with collision energy of
35 at a target value of 300,000.
Raw data were analyzed by Proteome Discoverer version 1.3.0.339
(Thermo Fischer Scientiﬁc). The data were searched against the
Swissprot database (version July 2013), using Mascot (Matrix Sci-
ence, London, UK). The search parameters included the use of trypsin
as proteolytic enzyme allowing up to a maximum of 2 missed cleav-
ages. The precursor mass tolerance was 0.8 Da and product ion toler-
ance of 0.6 Da. The following peptide ﬁlters were applied: a low
peptide conﬁdence, a Mascot ion score of at least 20 and a search en-
gine rank of 1.
2.5. Immuno-assays
Proteomic resultswere validatedwith enzyme linked immunosorbent
assays (ELISA) following the manufacturer's protocol (MyBioSource,
San Diego, CA, USA, or USCNK life science Inc. Hubei, China). The re-
searcher was blinded for clinical diagnosis of delirium. Optical density
of samples was measured with an iMark microplate absorbance reader
(Biorad), and compared to a standard curve run on the same plate.
Protein concentrations were calculated with SoftMax Pro Software
(version 5, Molecular Devices, Sunnyvale, CA, USA).
2.6. Statistical analysis
Proteomics datawere analysedwithDeCyder software. Analysis was
performed using paired Student t-tests with false discovery rate control,
a statistical method used in multiple hypotheses testing to correct for
multiple comparisons. It takes into account both the concern aboutmul-
tiple testing errors and the probability of a false rejection [20]. It is espe-
cially appropriate for exploratory analyses in which several signiﬁcant
results are expected in large numbers of tests. Compared to family
wise error rate correction procedures (such as the Bonferroni correc-
tion), false discovery rate procedures have greater power, but at the
cost of increased rates of type I errors.
All other statistics were performed using SPSS (SPSS for Windows,
version 20, IBM Corporation, Armonk, NY, USA). Numerical variables
are presented as median with interquartile range (IQR) or as mean
with standard deviation (SD). Categorical data were analysed using
Chi-square or Fisher-Exact test. Continuous variables were tested withMann–Whitney U tests or Student t-tests depending on sample size
and distribution of the data. A p-value ≤ 0.05was considered statistically
signiﬁcant. For visual presentation of ELISA data, GraphPad Prism 5 soft-
ware was used (GraphPad Software Inc., La Jolla, CA, USA).
3. Results
3.1. Patients
In the derivation cohort 53 patients were included, of whom 19
patients (35.8%) developed postoperative delirium (Table 1). In the
validation cohort 52 patients were included, of whom 11 patients
(21.2%) developed postoperative delirium. Patients' characteristics
between the derivation and validation cohort were similar, although
patients in the derivation studywere younger (median age, 83.1 year
vs 87.5 year, (p = 0.011) on average with a large overlap of the age
range. The median time between admission and surgery was longer
in the derivation group (p b 0.001). Within each cohort, patient's
characteristics and time between admission and surgery were simi-
lar between patients with and without postoperative delirium
(data not shown).
3.2. Proteomics
In the derivation group, CSF of 75 patients was collected. Eleven
additional patients were excluded because of preoperative delirium
(n = 3), or unclear labeling of samples (n = 7), or missing postopera-
tive delirium assessment (n = 1), leaving 64 patients for analysis in
this exploratory study. Of these 64 samples, 11 samples were excluded
because they had too low protein concentration, resulting in 53 CSF
samples for analysis. Mean CSF protein concentration after precipitation
did not differ between groups (delirium: 2.98 μg/μl (SD 1.27); control:
2.79 μg/μl (SD 1.35), p = 0.89). Half of the protein samples in each
group were labelled with Cy3, and half with Cy5. Seventeen proteins
were signiﬁcantly different between groups. Based on image analysis
(spot map is shown in Fig. 1), 16 proteins were selected for mass spec-
trometry. LC–MS/MS revealed 8 different proteins in 16 spots (Table 2).
Complement C3 was 1.4 fold lower in patients who developed post-
operative delirium, as were contactin-1 (−1.3 fold), ﬁbulin-1 (−1.2
fold) and I-beta-1,3-N-acetylglucosaminyltransferase (−1.2 fold).
Patients with postoperative delirium had higher levels of neural cell
adhesion molecule-2 (1.3 fold), haptoglobin (1.3 fold), zinc-α-2-
glycoprotein (1.3 fold) and ﬁbrinogen α-chain (1.2 fold), β-chain
(1.4 fold) and γ-chain (1.4 fold).
3.3. Validation
CSF of 67 patients was available for a validation study. Fifteen pa-
tients had to be excluded due to incomplete delirium scores (n = 1),
preoperative delirium (n = 1), pathological fracture (n = 1), or age
Fig. 1. a. Fluorescent spotmap: CSF proteins stainedwithﬂuorescent dye b. Spot pickingmapwith spot numbers: 600 μg of unlabelled protein extract, separated and stainedwith Flamingo
ﬂuorescent stain. The Flamingo stained gel was compared to DIGE master image, and differentially expressed spots manually designated.
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of validation can be found in Table 3 and Fig. 2. Patients with postoper-
ative delirium had signiﬁcantly higher C3 pre-operative concentrations
than control patients. Contactin-1 levels were lower in patients with
postoperative delirium, although not statistically signiﬁcant. C3a, C5a,
C5b-9, ﬁbrinogen, haptoglobin, neural cell adhesion molecule 2, ﬁbulin
1, zinc-α-2-glycoprotein and b3GNT3 levels did not differ between
groups. Analyses were repeated without cognitively impaired patients,
this did not reveal different outcomes. No statistical relevant correlation
was found between protein levels and age or time-to-surgery.
4. Discussion
We performed for the ﬁrst time 2D-DIGE on preoperative CSF
from hip fracture patients with and without postoperative deliriumand identiﬁed differences with respect to the levels of eight
proteins.
Only one prior study used proteomics on CSF of patients with delir-
ium [7]. Compared to Alzheimer's patients and hip fracture patients, the
presence of delirium was associated with dysregulation of acute phase
proteins C3, ﬁbrinogen and haptoglobin, which is in agreement with
the results of our proteomics study.
We found that concentrations of C3 were lower in patients with
postoperative delirium, which could be explained by complement acti-
vation, consistent with a role for neuroinﬂammation in delirium. The
complement system plays an important role in immunity [21]. Uncon-
trolled complement activity, however, has been associated with a
wide variety of inﬂammatory conditions and immune-complex diseases
such as autoimmune diseases, sepsis, Alzheimer's disease and rejection
of transplants [22]. No studies have been published on complement
Table 2
2D-DIGE results: altered protein quantity in CSF of patients with postoperative delirium.
Protein Spot nr MW (kDa) PSMs Mean score Av. ratio*
Contactin-1 365 113.2 19 6 −1.34
Complement C3 431 187 53 3.5 −1.35
434 63
NCAM-2 498 93 22 4 1.25
Fibulin-1 547 77.2 22 4 −1.2
Fibrinogen α-chain 942 94.9 12 8 1.19
Fibrinogen β-chain 1126 55.9 23 2 1.36
1134 5 11
1136 36 3
1144 38 1
b3GNT3 1198 47.1 4 12 −1.17
Fibrinogen γ-chain 1239 51.5 10 5 1.36
1246 30 2
1253 37 1
Zinc-α-2-glycoprotein 1422 34.2 21 2 1.34
Haptoglobin 1460 45.2 8 6 1.31
Av. ratio: average spot volume ratio between patients with postoperative delirium
and no postoperative delirium; b3GNT3: N-acetyllactosaminide beta-1,3-N-
acetylglucosaminyltransferase; MW: molecular weight (kilo Dalton); NCAM2: neural
cell adhesion molecule; PSMs: peptide-spectrum matches.
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proteins belong to the ﬁrst neuropathological changes in dementia
[23]. Old age and cognitive impairment are important risk factors for de-
lirium. To increase the external validity of our study, we did not exclude
patients with cognitive impairment. The underlying pathologic mecha-
nisms that increase the risk for delirium in older and cognitively im-
paired individuals are unknown. Our hypothesis was that differences
in CSF protein proﬁles could explain the difference in vulnerability in
delirium.
However, validation of these results in an independent, comparable
cohort, showed higher C3 concentrations in patients with postoperative
delirium. Our results and the variableﬁndings in previous research illus-
trate the complexity of the complement system. Especially C3 is hard to
investigate, as it is subject to continuous low grade spontaneous activa-
tion, the so called ‘C3 tickover’ [24]. Studies on CSF complement in pa-
tients with dementia show equally contradictory results [25–28]. A
possible explanation is that complement activation is dependent on
age and on stage of dementia [25,26]. Our two cohorts did not differ in
the number of patients with cognitive impairment, indicating that in-
consistent results do not seem to be attributable to differences in the
prevalence of dementia. Moreover, our results did not change once we
repeated analyses without cognitively impaired patients in the valida-
tion cohort.Table 3
Validation of 2D-DIGE results with ELISA: CSF preoperative protein concentrations.
No postoperative delirium median (IQR) P
C3 1411.8 (1037.1–1748.6) 2
C3a 2.57 (1.58–3.89) 4
C5a (pg/ml) 231.4 (144.5–308.7) 1
C5b-9 574.3 (468.8–724.9) 5
Fibrinogen 3213.2 (2076.7–4265.5) 3
Haptoglobin 2530.0 (1664.1–3109.9) 2
NCAM2 9.58 (5.77–11.63) 9
Fibulin-1 1206.5 (935.2–1686.6) 1
Contactin-1 53.6 (45.4–63.5) 4
ZAG (μg/ml) 17.3 (15.9–19.9) 1
b3GNT3 0.08 (0.06–0.11) 0
Results are presented in nanograms per millilitre, unless stated otherwise. b3GNT3: N-acetyl
Interquartile range; LLD: Lower limit of detection; and ZAG: zinc-alpha-2-glycoprotein.Another explanation for our inconsistent C3 results is the difference
in timebetween admission and surgery for both groups. It is known that
C3 levels rise due to the acute phase reaction after fracture [29]. Possibly
this initial inﬂammatory reaction is exaggerated in patients who
are prone to develop postoperative delirium. After some time, the com-
plement system is activated, which in these patients is characterized by
excessive splicing of C3, thereby inducing lower levels later on. This se-
quence of eventsmight explainwhy the proteomicsﬁndings, in patients
having longer waiting times, suggested lower CSF C3 levels, where the
immunoassay, in patients with shorter waiting times, suggested in-
creased CSF C3 levels in patients prone to develop delirium. However,
we did not ﬁnd a statistical relevant correlation between waiting time
and complement levels in our validation cohort.
To investigate whether complement activation might be held
responsible for low C3 levels, we assayed C3a, C5a and C5b-9. We did
not ﬁnd statistical relevant differences between groups.
Contactin-1 was also associated with the development of postoper-
ative delirium. Contactin-1 is a cell adhesion/recognition molecule of
the immunoglobulin superfamily [30]. Contactin-1 is expressed
exclusively on neurons [30]. It is critical for establishment of paranodal
axoglial junctions and for communication between axons and oligoden-
drocytes, the glial cells that form the myelin sheath [31]. We found
lower levels of contactin-1 in preoperative CSF of patients with postop-
erative delirium in the proteomics cohort. The importance of this
ﬁnding for delirium is not understood. We were able to replicate the
lower levels of contactin-1 in patients with postoperative delirium in
the validation cohort, though the trend did not reach statistical signiﬁ-
cance (p = 0.086), which might be due to the limited power of our
analysis.
Validationwith immunoassays in an independent cohortwith a sim-
ilar design as the derivation cohort showed no signiﬁcant differences in
any of the remainder of the identiﬁed proteinswith different proteomic
proﬁles between patients with and without delirium.
The number of patients (i.e., 11 patients with delirium in the valida-
tion cohort) precludesmultivariable analysis. Althoughwe corrected for
multiple testing, it is possible that our proteomic analysis generated
false positive results. Another option is contributable to methodological
aspects of 2D-DIGE. Some markers can be considered proteins that are
relatively easy to detect with this technique, which would account for
their frequent observation in proteomic studies on different diseases,
while they may not be especially speciﬁc indicators for the underlying
pathophysiological processes [32].
We deliberately validated results in a separate yet comparable co-
hort to assess the external validity of our ﬁndings. Both cohorts included
elderly patients with surgery after a hip fracture, all of whomwere free
of delirium at the time of CSF sampling, resulting in a study of associated
factors rather than markers of delirium.
There were some minor differences between the two cohorts. Pa-
tients in the validation group were somewhat older than patients in
the proteomics group. However, it is difﬁcult to understand how allegedostoperative delirium median (IQR) p-Value LLD
103.07 (1320.7–2763.0) 0.008 3.2
.56 (1.37–5.11) 0.329 0.064
58.40 (39.1–249.0) 0.257 29
84.82 (561.8–710.6) 0.779 12.86
645.37 (2632.0–4162.6) 0.533 4.1
652.43 (1789.7–4782.5) 0.319 4.7
.20 (6.0–12.3) 0.884 0.057
582.45 (955.9–1695.7) 0.720 0.18
5.76 (43.3–51.8) 0.086 0.108
8.30 (14.4–18.7) 0.712 0.48
.09 (0.04–0.13) 0.866 0.066
lactosaminide beta-1,3-N-acetylglucosaminyltransferase; C3: complement factor 3; IQR:
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obscure effects of processes driving the risk for delirium, which can be
hypothesized to be quite strong operators. Moreover, we did not ﬁnd
a statistical relevant correlation between age and C3 levels in our valida-
tion cohort. Although patients in the derivation cohort were younger,
they more frequently developed postoperative delirium, yet this did
not reach statistical signiﬁcance. Prospective cohorts show comparable
wide ranges, estimating an incidence stretching from 10 to 65% [33].
Furthermore, participants in the derivation cohort, but not in the val-
idation cohort, received routine care with low dose prophylactic halo-
peridol. No studies have been published on the effects of haloperidol
on acute phase proteins, yet it has been shown that long-term high-
dose haloperidol use does not affect serum and CSF levels of cytokines
in both healthy volunteers and schizophrenic patients [34–37]. It is
therefore not likely that low doses as administered in our study inﬂu-
enced protein levels. Since patients in the derivation cohort participated
in a clinical trial comparing taurine with placebo, we examined if
taurine administration might have inﬂuenced our results. We found
no signiﬁcant differences in CSF protein levels or in delirium incidence
between the intervention and placebo group.
More and more studies focus on CSF proteins in patients who are
prone to develop delirium or are acutely suffering from delirium [5,7,
38–40]. Although all of these studies of markers of trait or state, respec-
tively, report results that tend to support neuroinﬂammatory or neuro-
degenerative hypotheses, the results are not consistent. One previous
study assessed the CSF proteome in patients with delirium, and found
evidence for a neuroinﬂammatory hypothesis [7]. However, this study
compared a very heterogeneous group and had only small numbers of
patients. Our ﬁndings are based on a larger sample of patients and
validation has been performed in a very comparable cohort.
The present study illustrates the complexity of pathophysiological
mechanisms involved in delirium, emphasizing the importance of
validation in independent and largely comparable cohorts.Fig. 2. Validation of proteomics with ELISA: CSF protein concentrations shown as median with
plement component 3; LLD: lower limit of detection; NCAM2: neural cell adhesion molecule 25. Conclusion
Based on a proteomic analysis, we found alterations in 8 preopera-
tive CSF protein levels in patients with postoperative delirium, but we
were not able to replicate these results by immuno-assay in an indepen-
dent validation cohort. Our results show the complexity of pathophysi-
ological mechanisms involved in delirium. Furthermore, this study
emphasizes the need of independent validation of ﬁndings in proteomic
analyses.
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